Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to assess the time between the change from any anti TNF drug to Vedolizumab or Ustekinumab had an influence on the risk of treatment failure and the rate of adverse events or severe infections

Next Previous
X
Search
Trial Profile

A study to assess the time between the change from any anti TNF drug to Vedolizumab or Ustekinumab had an influence on the risk of treatment failure and the rate of adverse events or severe infections

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Dec 2020 New trial record
    • 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top